Abstract
BackgroundSemaglutide, a glucagon-like peptide-1 (GLP-1) analogue with an extended half-life of approximately 1 week has being come into clinic trial to treat parkingson’s disease but little is known about its effect to prevent against Alzheimer’s disease (AD). The goal of the present study was to explore the potential mechanisms of semaglutide to protect against AD. MethodsWe treated SH-SY5Y cell line with Aβ25-35 as an AD model. Further, SH-SY5Y cells damaged by Aβ25-35 were treated by semaglutide. Autophagy-related proteins and apoptosis-related proteins were measured to explore molecular mechanisms for semaglutide to protect against Aβ25-35. ResultsSemaglutide enhanced autophagy by increasing the expression of LC3II, Atg7, Beclin-1 and P62 which were inhibited by Aβ25-35. Further we showed that semaglutide inhibited apoptosis by inhibiting the expression of Bax induced by Aβ25-35 and increasing the expression of Bcl2 inhibited by Aβ25-35. ConclusionOur results provide a clue for the hypothesis that autophagy enhancement and apoptosis inhibition may be involved in the effect of semaglutide to protect against Aβ 25-35.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
